Pharma vet Valeria Fantin jumps to oncology team at Gilead; João Siffert out as Abeona looks for another CEO
→ News broke on Twitter yesterday that Valeria Fantin has headed to Gilead to be their VP, oncology research, a field in which CEO Dan O’Day has placed particular emphasis with the $21 billion acquisition of Immunomedics.
The well-traveled biopharma exec just completed a brief run as CSO at Zai Lab and has also been CSO at ORIC Pharmaceuticals. Fantin, who started out in epigenetics and kinase drug discovery at Merck in 2004, then moved to ARIAD Pharmaceuticals in 2008, only to quickly pivot to Agios Pharmaceuticals not long after its inception as a molecular oncology director. After Agios, she was VP, tumor cell biology at Pfizer, helping develop Ibrance and discover Lorbrena.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.